Despite being highly preventable, cervical cancer is the fourth most common cancer and
cause of cancer death in women globally. In low‐income countries, cervical cancer is often …

Infections with human papillomavirus (HPV) are common and transmitted by direct contact.
Although the great majority of infections resolve within 2 years, 13 phylogenetically related …

Background Primary analyses of a study in young women aged 16–26 years showed
efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52 …

This report summarizes the epidemiology of human papillomavirus (HPV) and associated
diseases, describes the licensed HPV vaccines, provides updated data from clinical trials …

Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …

End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV)
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …

Strong evidence now supports the adoption of cervical cancer prevention strategies that
explicitly focus on persistent infection with the causal agent, human papillomavirus (HPV) …

Background The quadrivalent human papillomavirus (qHPV) vaccine prevented vaccine
HPV type-related infection and disease in young women in the 4-year FUTURE II efficacy …

The article presents recommendations on the use of quadrivalent papillomavirus vaccine
(HVP4) in males by the Advisory Committee on Immunization Practices (ACIP) in 2011. The …

The discovery that certain high-risk strains of human papillomavirus (HR-HPV) cause nearly
100% of invasive cervical cancer has spurred a revolution in cervical cancer prevention by …